Teva launches generic Abilify tabs

JERUSALEM — Teva Pharmaceutical announced the launch of aripiprazole tablets in 2-, 5-, 10-, 15, 20- and 30-mg strengths in the United States. According to the company, the drug — a generic version of Abilify tablets — is used to treat schizophrenia as well as the acute treatment of manic and mixed episodes associated with bipolar I disorder. 

 

Schizophrenia is a long-term illness that alters a person’s ability to think clearly, manage their motions and make decisions, Teva stated, adding that one percent of Americans live with the illness. People dealing with schizophrenia may experience such symptoms as hallucinations, trouble with thinking and concentration and lack of motivation.  

 

Bipolar I is characterized by manic or mixed episodes where a person experiences extreme irritability or euphoria. According to Teva, it’s the most severe form of the illness because of the extreme manic episodes associated with it. 

 

“Our commitment at Teva is to make affordable, high-quality generic medicines available to millions of patients every day. We are pleased to launch generic Aripiprazole tablets and offer a generic treatment for patients suffering from schizophrenia and bipolar I disorder,” said Siggi Olafsson, president and CEO, global generic medicines for Teva.

 

Abilify tablets are marketed by Otsuka Pharmaceutical. The drug had annual sales of $7.8 billion in the United States as of December 2014, according to IMS data.